Branded Legacy, Inc. Advances Revolutionary Intranasal Drug Delivery with Unitary Device Mold Development
Branded Legacy (OTC:BLEG) announced on October 27, 2025 that subsidiary BioLegacy Evaluative Group initiated engineering and development of a unitary device mold for its air-driven intranasal drug delivery platform.
The milestone advances scalable production of a single-use device intended for rapid, consistent delivery of therapeutics, including an inhaled naloxone program, and aligns with the company’s User Requirements Specification (URS). The work follows a provisional patent filing in September 2025 and complements a GMP-compliant manufacturing facility opened September 23, 2025 in Vancouver to support high-volume, cost-effective manufacturing for global pharmaceutical standards.
Branded Legacy (OTC:BLEG) ha annunciato il 27 ottobre 2025 che la controllata BioLegacy Evaluative Group ha avviato l'ingegneria e lo sviluppo di uno stampaggio per dispositivo unitario per la sua piattaforma di somministrazione di farmaci intranasale azionata dall'aria.
Il traguardo facilita una produzione scalabile di un dispositivo usa-e-getta destinato a una somministrazione rapida e coerente di terapie, incluso un programma di naloxone inalata, e si allinea con la Specificazione dei Requisiti dell'Utente (URS) dell'azienda. Il lavoro segue una domanda di brevetto provvisoria presentata nel settembre 2025 e completa un impianto di produzione conforme alle GMP aperto il 23 settembre 2025 a Vancouver per supportare una produzione ad alto volume, a costi contenuti, per standard farmaceutici globali.
Branded Legacy (OTC:BLEG) anunció el 27 de octubre de 2025 que su subsidiaria BioLegacy Evaluative Group inició la ingeniería y el desarrollo de un molde de dispositivo unitario para su plataforma de entrega de fármacos intranasal impulsada por aire.
El hito impulsa una producción escalable de un dispositivo de un solo uso destinado a una entrega rápida y constante de terapéuticas, incluido un programa de naloxona inhalada, y se alinea con la Especificación de Requisitos del Usuario (URS) de la empresa. El trabajo sigue una solicitud de patente provisional presentada en septiembre de 2025 y complementa una instalación de fabricación conforme a GMP abierta el 23 de septiembre de 2025 en Vancouver para respaldar una fabricación de alto volumen y costo-eficiente para estándares farmacéuticos globales.
브랜디드 레거시(OTC:BLEG)가 2025년 10월 27일 자회사 BioLegacy Evaluative Group가 공기 구동 비강 내 약물 전달 플랫폼용 단일 장치 몰드의 엔지니어링 및 개발을 시작했다고 발표했습니다.
이 이정표는 일회용 장치의 확장 생산을 촉진하여 신속하고 일관된 치료제 전달이 가능하도록 하며, 흡입형 나록손 프로그램을 포함하고, 회사의 사용자 요구사항 명세(URS)에 부합합니다. 이 작업은 2025년 9월에 출원된 임시 특허를 따르며 2025년 9월 23일에 개소한 GMP 준수 제조 시설를 보완하여 글로벌 제약 표준에 맞춘 대용량, 비용 효율적인 제조를 밴쿠버에서 지원합니다.
Branded Legacy (OTC:BLEG) a annoncé le 27 octobre 2025 que sa filiale BioLegacy Evaluative Group a entamé l'ingénierie et le développement d’un moule de dispositif unitaire pour sa plateforme de délivrance de médicaments intranasale entraînée par l’air.
Cette étape fait progresser la production évolutive d’un dispositif jetable destiné à une administration rapide et homogène des thérapeutiques, y compris un programme de naloxone inhalée, et s’aligne sur la Spécification des Exigences Utilisateur (URS) de l’entreprise. Le travail suit une demande de brevet provisoire déposée en septembre 2025 et complète une installation de fabrication conforme GMP ouverte le 23 septembre 2025 à Vancouver pour soutenir une fabrication à haut débit et rentable selon les normes pharmaceutiques mondiales.
Branded Legacy (OTC:BLEG) kündigte am 27. Oktober 2025 an, dass die Tochtergesellschaft BioLegacy Evaluative Group die Entwicklung und Konstruktion einer Einheitgerät-Form für ihre luftgetriebene intranasale Medikamentenabgabe-Plattform aufgenommen hat.
Der Meilenstein erleichtert die skalierbare Herstellung eines Einweggeräts, das eine schnelle, konsistente Abgabe von Therapeutika ermöglicht, einschließlich eines inhalierbaren Naloxon-Programms, und entspricht der User Requirements Specification (URS) des Unternehmens. Die Arbeiten folgen einer vorläufigen Patentanmeldung im September 2025 und ergänzen eine GMP-konforme Fertigungsanlage, die am 23. September 2025 in Vancouver eröffnet wurde, um eine hochvolumige, kosteneffiziente Herstellung für globale pharmazeutische Standards zu unterstützen.
أعلنت Branded Legacy (OTC:BLEG) في 27 أكتوبر 2025 أن الشركة الفرعية BioLegacy Evaluative Group بدأت الهندسة وتطوير قالب جهاز وحدة لمنصة توصيل الدواء الأنفي المدفوعة بالهواء.
هذه المرحلة تعزز الإنتاج القابل للتوسع لجهاز استخدام واحد يهدف إلى التوصيل السريع والمتسق للعلاجات، بما في ذلك برنامج naloxone المستنشق، وتتماشى مع مواصفة متطلبات المستخدم (URS) للشركة. يأتي العمل بعد تقديم طلب براءة اختراع مؤقت في سبتمبر 2025 ويكمل منشأة تصنيع مطابق لـ GMP افتتحت في 23 سبتمبر 2025 في فانكوفر لدعم تصنيع عالي الحجم وبتكلفة فعّالة وفق المعايير الدوائية العالمية.
Branded Legacy (OTC:BLEG) 于 2025年10月27日宣布，其子公司 BioLegacy Evaluative Group 已启动为其空气驱动的鼻腔药物递送平台设计的 单一设备模具 的工程与开发。
该里程碑推动可扩展生产，用于快速、稳定地递送药物的一次性设备，包括吸入型纳洛酮计划，并与公司的人机需求规格（URS）保持一致。该工作在 2025 年 9 月提出的临时专利申请之后进行，并补充了于 2025 年 9 月 23 日在温哥华开设的符合 GMP 的制造设施，以支持全球药品标准的高产量、成本效益制造。
- Unitary mold development initiated on October 27, 2025
- Provisional patent filed in September 2025 for the air-driven intranasal device
- GMP facility opened on September 23, 2025 in Vancouver to enhance production capabilities
- Patent status is provisional only as of September 2025 and not yet granted
Pioneering Precision Engineering to Transform Global Therapeutics Delivery
VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (OTC:BLEG), a leader in innovative addiction treatment and harm reduction solutions, today announced that its subsidiary, BioLegacy Evaluative Group Inc., has initiated engineering and development of a unitary device mold for its proprietary air-driven intranasal drug delivery platform. This milestone marks a significant step toward scalable production of its groundbreaking single-use device, designed to deliver rapid, consistent, and reliable therapeutics, including its flagship inhaled naloxone program.
The unitary device mold defines the form and function of the innovative air-driven system, ensuring precision and scalability in alignment with the company’s rigorous User Requirements Specification (URS). This development paves the way for high-volume, cost-effective manufacturing to meet global pharmaceutical standards.
“This is a key technical milestone that bridges concept to commercial manufacturing,” said Mark O’Connor, Product Development Manager at BioLegacy Evaluative Group. “By advancing the mold design in accordance with our URS framework, we’re ensuring that every production step from material selection to form and function meets the standards required for global pharmaceutical deployment.”
This achievement builds on Branded Legacy’s recent momentum, including the September 2025 filing of a provisional patent for its Air-Driven Unitary Intranasal Drug Delivery Device for Stable and Reconstitutable Medicaments, as announced on GlobeNewswire. It also complements the company’s newly established GMP-compliant manufacturing facility in Vancouver, unveiled on September 23, 2025, which enhances production capabilities for life-saving therapies. Together, these advancements position Branded Legacy to address critical public health challenges, such as the opioid crisis, with affordable and accessible solutions.
Watch a short video of Dr. Mark O’Connor outlining the mold engineering process on our X page this afternoon: https://x.com/BrandedLegacy
About BioLegacy Evaluative Group, Inc.
BioLegacy Evaluative Group Inc. is a life sciences company dedicated to developing innovative therapies and devices addressing urgent global health challenges. With strategic partnerships at McMaster University and Stanford University, and a newly acquired GMP-compliant manufacturing facility, BioLegacy is positioned to deliver scalable, cost-effective solutions in areas of high unmet need.
About Branded Legacy, Inc.
Branded Legacy, Inc. (OTC:BLEG) is a forward-thinking holdings company dedicated to pioneering solutions in addiction treatment and harm reduction. Through its subsidiary, BioLegacy Evaluative Group, and strategic collaborations with leading institutions like McMaster University and Stanford University, the company drives transformative research and innovation. With a state-of-the-art GMP manufacturing facility in Vancouver, Branded Legacy leverages advanced production capabilities to deliver cutting-edge products, positioning itself as a leader in addressing critical public health challenges. For more information, visit www.brandedlegacy.com.
Investor Relations
Branded Legacy, Inc.
Email: info@brandedlegacy.com
Phone: 877-250-9077
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including projections regarding market growth, revenue potential, and development timelines, are based on current expectations and beliefs and involve risks and uncertainties that could cause actual results to differ materially. Branded Legacy undertakes no obligation to update these statements except as required by law.
InvestorWire Service Contact:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
FAQ
What did Branded Legacy (BLEG) announce on October 27, 2025 about its intranasal device?
How does the September 2025 provisional patent affect BLEG's intranasal device plans?
When did Branded Legacy open its GMP-compliant manufacturing facility for BLEG products?
Will the unitary device mold support naloxone distribution for BLEG?
What investor timeline is associated with BLEG's mold development announcement on October 27, 2025?
Does the October 2025 announcement indicate regulatory approval for BLEG's intranasal device?
